secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001213900-22-068992
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Therapeutics Q3 2022 net loss narrows to $59M; cash at $546M, runway through mid-2025
--------------------------------------------------------------------------------

- Cash and investments at $546.4M at Sep 30, down from $628.2M at Q2 end; cash runway through mid-2025.
- Net loss Q3 $59.0M ($0.31 per share) vs $129.7M ($0.70) year ago; revenue $23.6M (non-cash royalty).
- R&D expense fell to $33.6M from $103.7M due to wind-down of bempegaldesleukin program.
- Restructuring/impairment costs $124.3M year-to-date, including $58.5M non-cash lease/equipment impairment.
- Pipeline: NKTR-358 (w/ Lilly) proof-of-concept in atopic dermatitis; NKTR-255 Phase 2 in large B-cell lymphoma planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390022068992/0001213900-22-068992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390022068992/ea167983-8k_nektarther.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-068992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer